CMPS

#2650
COMPASS Pathways Plc American Depository Shares
5.7500 USD
-0.35%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.7500
5.7500
Intervallo Annuale
4.8800
8.9000
Variazione giornaliera
-0.35%
Variazione Mensile
-10.58%
Variazione di 6 mesi
-9.73%
Variazione Annuale
-9.73%
Chiusura Precedente
5.7700
Apertura
5.7500
Bid
Ask
Minimo
5.7500
High
5.7500
Volume
60
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 202020212022202320242025 TTM

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Notizie